| A Study to Assess the Efficacy and Safety of Solriamfetol in Children With ADHD (NCT07717879) | Axsome Therapeutics, Inc. | 2026-07-06 |
| A Study to Assess the Efficacy and Safety of Solriamfetol in Adolescents With ADHD (NCT07717892) | Axsome Therapeutics, Inc. | 2026-06-25 |
| Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia (NCT07637162) | Axsome Therapeutics, Inc. | 2026-04-29 |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol (NCT07484217) | Axsome Therapeutics, Inc. | 2026-02-23 |
| Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design (NCT07398417) | Axsome Therapeutics, Inc. | 2026-01-14 |
| A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder (NCT06878976) | Axsome Therapeutics, Inc. | 2025-02-20 |
| An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study (NCT06736509) | Axsome Therapeutics, Inc. | 2024-11-21 |
| Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol (NCT06413433) | Axsome Therapeutics, Inc. | 2024-04-26 |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms (NCT06223880) | Axsome Therapeutics, Inc. | 2023-12-27 |
| A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) (NCT05972044) | Axsome Therapeutics, Inc. | 2023-07-06 |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation (NCT05557409) | Axsome Therapeutics, Inc. | 2022-09-06 |
| Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) (NCT05550207) | Axsome Therapeutics, Inc. | 2022-08-31 |
| A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) (NCT05113745) | Axsome Therapeutics, Inc. | 2021-10-20 |
| A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy (NCT05059223) | Axsome Therapeutics, Inc. | 2021-09-15 |
| Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration (NCT05008341) | Axsome Therapeutics, Inc. | 2021-08-27 |
| Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (NCT04789174) | Axsome Therapeutics, Inc. | 2021-05-17 |
| An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients (NCT04971291) | Axsome Therapeutics, Inc. | 2021-04-14 |
| Assessing Clinical Outcomes in Alzheimer's Disease Agitation (NCT04797715) | Axsome Therapeutics, Inc. | 2020-12-31 |
| Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) (NCT04634669) | Axsome Therapeutics, Inc. | 2020-09-23 |
| Mechanistic Evaluation of Response in TRD (MERIT) (NCT04608396) | Axsome Therapeutics, Inc. | 2020-08-13 |
| Initiating Early Control of Migraine Pain and Associated Symptoms (NCT04163185) | Axsome Therapeutics, Inc. | 2019-10-08 |
| SUNOSI® (Solriamfetol) Pregnancy Registry (NCT06413420) | Axsome Therapeutics, Inc. | 2019-07-31 |
| Open-Label Safety Study of AXS-05 in Subjects With Depression (NCT04039022) | Axsome Therapeutics, Inc. | 2019-07-08 |
| Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) (NCT04068051) | Axsome Therapeutics, Inc. | 2019-07-06 |
| A Trial of AXS-05 in Patients With Major Depressive Disorder (NCT04019704) | Axsome Therapeutics, Inc. | 2019-06-20 |
| Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) (NCT03881852) | Axsome Therapeutics, Inc. | 2019-04-05 |
| Maximizing Outcomes in Treating Acute Migraine (NCT03896009) | Axsome Therapeutics, Inc. | 2019-03-04 |
| Assessing Symptomatic Clinical Episodes in Depression (NCT03595579) | Axsome Therapeutics, Inc. | 2018-05-30 |